Bausch + Lomb rises 13% on potential sale chatter

Bausch + Lomb rises 13% on potential sale chatter
Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal
After IPO, Bausch + Lomb turns to an industry favorite to run the company
6.28BUSD
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
CA0717051076
CUSIP
-
Sector
Healthcare
Industry
Medical Instruments & Supplies
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.89
Book Value
18.09
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.49
Wall Street Target Price
19.39
EPS Estimate Current Year
0.81
EPS Estimate Next Year
1.11
EPS Estimate Current Quarter
0.1606
EPS Estimate Next Quarter
0.218
Most Recent Quarter
-
Revenue TTM
5,324,000,256
Gross Profit TTM
3,271,000,064
EBITDA
816,000,000
Profit Margin
-3.21%
Return On Assets TTM
1.83%
Return On Equity TTM
-2.52%
Revenue Per Share TTM
14.987
Qtly Revenue Growth YOY
9.10%
Diluted Eps TTM
-0.49
Qtly Earnings Growth YOY
-88.60%
Trailing PE
0.00
Forward PE
16
Price Sales TTM
1.1821
Price Book MRQ
0.9848
Enterprise Value Revenue
2
Enterprise Value EBITDA
15
405.16
1.76%452.00
1.54%254.00
1.45%197.00
1.26%32.51
0.55%69.83
0.17%195.78
-2.35%99.11
-2.10%167.81
-1.43%169.14
-0.34%